Answers are grounded in this paper and cite their sources.
Recent advances in understanding the pathogenesis of autoimmune diseases, including lupus erythematosus, dermatomyositis, and scleroderma, have allowed for reorganization of the classification of these disorders. With these novel stratifications, early identification of rheumatic skin diseases with systemic implications and consistency in designing and executing therapeutic trials will be enhanced. This review will provide a compilation of updates on epidemiology, pathology, evaluation, and classification with a predominant focus on therapeutics, reflecting the growth is this area.
No takes yet. Share an insight, caveat, or question.
Costner et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: